2-imidazol-1-ylethyl 4-[(4-methoxyphenyl)-amino]-6-(methylcarbamoyl)-quinoline-3-carboxylate | 1256485-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-imidazol-1-ylethyl 4-[(4-methoxyphenyl)-amino]-6-(methylcarbamoyl)-quinoline-3-carboxylate
• 英文别名: 2-imidazol-1-ylethyl 4-[(4-methoxyphenyl)amino]-6-(methylcarbamoyl)-quinoiine-3-carboxylate；2-Imidazol-1-ylethyl 4-[(4-methoxyphenyl)amino]-6-(methylcarbamoyl)quinoline-3-carboxylate；2-imidazol-1-ylethyl 4-(4-methoxyanilino)-6-(methylcarbamoyl)quinoline-3-carboxylate
• CAS: 1256485-34-3
• 化学式: C₂₄H₂₃N₅O₄
• 分子量: 445.478
• InChiKey: LWKAZIAVOFAKGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-(2-羟乙基)咪唑 、 4-[(4-methoxyphenyl)amino]-6-(methyl-carbamoyl)quinoline-3-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以23%的产率得到2-imidazol-1-ylethyl 4-[(4-methoxyphenyl)-amino]-6-(methylcarbamoyl)-quinoline-3-carboxylate
  参考文献：
  名称：

  [EN] SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS
  [FR] QUINOLÉINES SUBSTITUÉES POUR UNE UTILISATION EN TANT QU'INHIBITEURS DE VEGF

  摘要：

  公式（I）的化合物，以及其药学上可接受的盐和包含化合物的治疗有效量的药物组合物。该化合物在治疗癌症、糖尿病视网膜病变、年龄相关性黄斑变性、炎症、中风、缺血性心肌、动脉粥样硬化、黄斑水肿和牛皮癣方面有用。

  公开号：

  WO2010133669A1

文献信息

• SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS
  申请人：Malm Johan

  公开号：US20120065199A1

  公开（公告）日：2012-03-15

  A compound of formula (I) as well as pharmaceutically acceptable salts thereof and pharmaceutical compositions including a therapeutically effective amount of the compounds. The compound is useful in treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema and psoriasis.

  该化合物的化学式为（I），其药用盐和制药组合物包括一定量的该化合物，可用于治疗癌症、糖尿病性视网膜病变、老年性黄斑变性、炎症、中风、缺血性心肌、动脉粥样硬化、黄斑水肿和牛皮癣。
• Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases
  申请人：Clanotech AB

  公开号：US20150031723A1

  公开（公告）日：2015-01-29

  A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.
• US9376393B2
  申请人：——

  公开号：US9376393B2

  公开（公告）日：2016-06-28
• [EN] QUINOLINE COMPOUNDS WHICH ARE ANTI-ANGIOGENIC INTEGRIN ALPHA5 BETAL INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS OR FIBROSIS-RELATED DISEASES<br/>[FR] COMPOSÉS QUINOLÉINE UTILISÉS COMME INHIBITEURS DE L'INTÉGRINE ALPHA5 BÊTA1 ANTI-ANGIOGÉNIQUES POUR TRAITER UNE FIBROSE OU DES MALADIES LIÉES À UNE FIBROSE
  申请人：CLANOTECH AB

  公开号：WO2013103317A1

  公开（公告）日：2013-07-11

  A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.